With Anxa2 being shown to gradually upregulate throughout the evolution of pSS to pSS/MALT, Cui et al. [42] have suggested that this protein most likely contributes to the pathophysiology of SS development, thereby representing a potential biomarker of disease progression and lymphoproliferation in SS patients, as well as progression to MALT. Here, ANXA2 is linked to synovial sarcoma.